EP Patent

EP3466953A1 — Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor

Assigned to Incyte Holdings Corp · Expires 2019-04-10 · 7y expired

What this patent protects

The present invention provides the use of 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile in the preparation of a medicament for use in the treatment of graft versus host disease.

USPTO Abstract

The present invention provides the use of 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile in the preparation of a medicament for use in the treatment of graft versus host disease.

Drugs covered by this patent

Patent Metadata

Patent number
EP3466953A1
Jurisdiction
EP
Classification
—
Expires
2019-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Holdings Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.